Keywords: Molecuolar Insight, Onalta, metastatic carcinoid tumors
Molecular Insight stock leaps nearly 200% on strong new Phase II Onalta data
Article | 14 April 2010
Massachusetts, USA-based Molecular Insight Pharmaceuticals saw its share price rocket nearly 200% to $4.43 in pre-market trading yesterday, after the company announced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
